Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
26. September 2024 07:02 ET
|
Pasithea
Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.
Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis
13. August 2024 08:00 ET
|
Biomed Valley Discoveries, Inc.
Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
13. Juni 2024 06:59 ET
|
Pasithea
Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
28. Mai 2024 06:59 ET
|
Pasithea
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
04. Januar 2024 08:00 ET
|
Quanta Therapeutics, Inc.
QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
12. Dezember 2023 08:00 ET
|
Immuneering Corporation
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
11. Oktober 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
29. Juni 2023 08:29 ET
|
Pasithea
PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
14. März 2023 16:30 ET
|
Immuneering Corporation
Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment Biomarker discovery and clinical translation supports patient selection in ongoing Phase 1/2a clinical...
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
06. März 2023 16:05 ET
|
Immuneering Corporation
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected...